title: Influence of JC virus coding region genotype on risk of multiple sclerosis and progressive multifocal leukoencephalopathy.
abstract: Two features of the biology of JC virus make it a particularly suitable candidate for an agent in MS-like disease: its neurotropic capability targeting glial cells as evidenced in progressive multifocal leukoencephalopathy lesions, and its capacity for latency and persistence as illustrated by its behaviour in the kidney. JC virus is chronically or intermittently excreted in the urine by some 40% of the population. The existence of JC virus in multiple coding-region genotypes provides a unique approach to the study of JC virus-induced neurological disease. We have previously shown that a genotype originating in Asia but also present in Europe and the US, called Type 2B, is more frequently found in PML brain than expected based on its prevalence in urine samples from a control population. In contrast, we find that the excretion of JCV in MS patients is similar in both genotype and frequency to that of control individuals, and appears to be regulated by factors unrelated to those that control CNS disease activity.
authors.affiliation: Neurotoxicology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, MD 20892, USA.
authors.forename: H T
authors.initials: HT
authors.lastname: Agostini
authors.forename: C F
authors.initials: CF
authors.lastname: Ryschkewitsch
authors.forename: R W
authors.initials: RW
authors.lastname: Baumhefner
authors.forename: W W
authors.initials: WW
authors.lastname: Tourtellotte
authors.forename: E J
authors.initials: EJ
authors.lastname: Singer
authors.forename: S
authors.initials: S
authors.lastname: Komoly
authors.forename: G L
authors.initials: GL
authors.lastname: Stoner
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000956:Antigens, Viral / Q000134:cerebrospinal fluid / Q000652:urine; D022762:CCAAT-Enhancer-Binding Proteins; D015331:Cohort Studies; D004268:DNA-Binding Proteins / Q000235:genetics; D003711:Demyelinating Diseases / Q000821:virology; D018450:Disease Progression; D005260:Female; D005814:Genes, Viral / Q000235:genetics; D005838:Genotype; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage; D007577:JC Virus / Q000235:genetics* / Q000302:isolation & purification; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy / Q000208:ethnology / Q000821:virology*; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000208:ethnology / Q000821:virology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000208:ethnology / Q000821:virology*; D051839:NFI Transcription Factors; D009457:Neuroglia / Q000821:virology; D009687:Nuclear Proteins; D012045:Regulatory Sequences, Nucleic Acid; D012307:Risk Factors; D014157:Transcription Factors; D051840:Y-Box-Binding Protein 1
chemical_list: D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D022762:CCAAT-Enhancer-Binding Proteins; D004268:DNA-Binding Proteins; D051839:NFI Transcription Factors; D009687:Nuclear Proteins; D014157:Transcription Factors; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a